GlassScriptPhysician profile
Robert Dukjun Yoo
NPI 1699035717
$43,658.97
in general payments reported to CMS, 2019-2025
71 companies · $7,755 in 2025
The $7,755 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,987 · 2020: $2,275 · 2021: $8,454 · 2022: $5,531 · 2023: $2,155 · 2024: $16K · 2025: $7,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $4,612 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,070 · Honoraria: $375 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,170.00 |
| Food and Beverage | $4,612.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,070.00 |
| Honoraria | $375.00 |
| Education | $184.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $6,089.33 | 2020-2025 | Pemazyre, Monjuvi, Jakafi |
| Regeneron Pharmaceuticals, INC. | $5,031.17 | 2023-2024 | Libtayo |
| Daiichi Sankyo INC. | $4,808.61 | 2019-2025 | Vanflyta, Enhertu |
| Astrazeneca Pharmaceuticals LP | $3,046.35 | 2019-2025 | Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $2,545.67 | 2019-2025 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $2,342.51 | 2020-2025 | Tazverik, Onivyde |
| Karyopharm Therapeutics INC. | $2,275.74 | 2021-2024 | Xpovio |
| Jazz Pharmaceuticals INC. | $2,072.16 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $1,925.00 | 2024 | Imbruvica |
| Janssen Biotech, INC. | $1,808.21 | 2019-2025 | Erleada, Darzalex, Talvey |
| Servier Pharmaceuticals LLC | $1,745.72 | 2021-2025 | |
| Pfizer INC. | $811.74 | 2019-2025 | |
| Geron Corporation | $780.00 | 2025 | Rytelo |
| Novartis Pharmaceuticals Corporation | $769.55 | 2019-2025 | |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.